本帖最后由 橙色雨丝 于 2016-2-17 10:50 编辑
Bone Marrow Transplantation ,(8 February 2016)
Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas
F Heinzelmann, W Bethge, D W Beelen, MEngelhard, N Kröger, P Dreger, D Niederwieser, J Finke, D Bunjes, J Tischer, GKobbe, E Holler, M Bornhäuser, M Stelljes, H Baurmann, A Müller, I Haubitz, HSchrezenmeier, C Müller and H Ottinger
Abstract
Allogeneic hematopoietic cell transplantation (HCT) offers the chance of cure for patients with non-transformed follicular lymphoma (FL), but is associated with the risk of non-relapse mortality (NRM).
The aim of this study was to identify subgroups of FL patients who benefit from HCT.
The European Society for Blood and Marrow Transplantation (EBMT) Minimum-Essential-A Data of 146 consecutive patients whoreceived HCT for FL between 1998 and 2008 were extracted from the database ofthe German Registry ‘DRST’.
Diagnosis of FL was verified by contact with the reference pathologists. Estimated 1-, 2- and 5-year overall survivals(OS) were 67%, 60% and 53%, respectively. Day 100 NRM was 15%. Thirteen out of 33 patients (40%) with treatment-refractory disease (RD) at the time of transplantation survived long term. Univariate statistical analysis suggested limited chronic GvHD, donor age <42 years and TBI-based conditioning intreatment refractory patients to correlate with favorable OS. Independent prognostic factors for OS were treatment-sensitive disease and limited chronicGvHD for the whole cohort, and additionally TBI-based conditioning for the treatment refractory subgroup. In contrast, patient age >55 years had no impact on outcome. Thus, HCT for FL is associated with acceptable NRM, and offers a substantial chance of cure for patients with RD or advanced age. Donors <42 years should be preferred if available.
| 
/1 
窥视卡
雷达卡
发表于 2016-2-17 10:32:08
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
抢沙发
显身卡
楼主
发表于 2016-2-17 10:54:40
